Vanguard Group
INKT icon

Vanguard Group’s MiNK Therapeutics INKT Stock Holding History

Vanguard Group’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$754K Buy
67,651
+34,300
+103% +$443K ﹤0.01% 3845
2025
Q3 		$467K Buy
33,351
+9,607
+40% +$154K ﹤0.01% 3968
2025
Q2 		$178K Hold
23,744
– – ﹤0.01% 4099
2025
Q1 		$205K Buy
23,744
+326
+1% +$2.9K ﹤0.01% 4072
2024
Q4 		$163K Hold
23,418
– – ﹤0.01% 4125
2024
Q3 		$176K Hold
23,418
– – ﹤0.01% 4153
2024
Q2 		$222K Hold
23,418
– – ﹤0.01% 4150
2024
Q1 		$213K Hold
23,418
– – ﹤0.01% 4170
2023
Q4 		$251K Hold
23,418
– – ﹤0.01% 4186
2023
Q3 		$258K Sell
23,418
-700
-3% -$11.4K ﹤0.01% 4204
2023
Q2 		$506K Buy
24,118
+19,207
+391% +$385K ﹤0.01% 4119
2023
Q1 		$93.1K Hold
4,911
– – ﹤0.01% 4415
2022
Q4 		$128K Hold
4,911
– – ﹤0.01% 4365
2022
Q3 		$104K Buy
+4,911
New +$96.7K ﹤0.01% 4489
2022
Q2 		– Sell
-1,035
Closed -$23K – 4629
2022
Q1 		$23K Sell
1,035
-42
-4% -$1.26K ﹤0.01% 4624
2021
Q4 		$48K Buy
+1,077
New +$128K ﹤0.01% 4626

Other funds holding INKT

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's INKT Position: Q4 2025 in Review

Vanguard Group increased its MiNK Therapeutics (INKT) stake by 103% in Q4 2025, buying an estimated $443K and bringing the position to 67,651 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #3845.

Vanguard Group first reported a position in INKT in Q4 2021 and has held it in 16 quarters since. 25 funds tracked by Wall St. Rank hold INKT as of Q4 2025.

  • Vanguard Group held 67,651 shares of MiNK Therapeutics worth $754K as of Q4 2025.
  • Vanguard Group bought 34,300 MiNK Therapeutics shares in Q4 2025, an estimated $443K.
  • MiNK Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3845 holding.
  • Vanguard Group first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • 25 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.